It is administered orally as a once-daily dose. Archives of sexual behavior, 18(3), 217-228.Gooren, L., Spinder, T., Spijkstra, J. J., Van Kessel, H., Smals, A., Rao, B. R., & Hoogslag, M. (1987). Turkiye Klinikleri Journal of Endocrinology-Special Topics, 2(2), 110.Erem, C. (2013). Bicalutamide and third-generation aromatase inhibitors in testotoxicosis. (2009). Because bicalutamide does not lower androgen levels, it may be a particularly favorable antiandrogen for transgender women who wish to help preserve sex drive, sexual function, and/or fertility, as antiandrogens that strongly suppress levels of testosterone and its metabolites, such as CPA and GnRH modulators, can greatly disrupt these functions. [191] randomized 52 men with prostate cancer (and no bone metastases) to bicalutamide 150 mg/day or to the GnRH agonist leuprolide. CasodexTM 10–200 mg daily, used as monotherapy for the treatment of patients with advanced prostate cancer. Acta Clinica Belgica, 68(4), 268-274.Kreher, N. C., Pescovitz, O. H., Delameter, P., Tiulpakov, A., & Hochberg, Z. E. (2006). (1989). (Ed.). ScienceDirect ® is a registered trademark of Elsevier B.V.URL: Hormonal for Castrate-Resistant Prostate CancerJaspreet Singh Parihar MD, Isaac Yi Kim MD, PhD, in Derek G. Waller BSc (HONS), DM, MBBS (HONS), FRCP, Anthony P. Sampson MA, PhD, FHEA, FBPhS, in Medical Pharmacology and Therapeutics (Fifth Edition)A worldwide yearly survey of new data in adverse drug reactionsStan K. Bardal BSc (Pharm), MBA, PhD, ... Douglas S. Martin PhD, in Williams Textbook of Endocrinology (Thirteenth Edition)Antiandrogen Monotherapy in the Treatment of Prostate CancerZachary Piotrowski MD, Richard E. Greenberg MD, FACS, in A worldwide yearly survey of new data in adverse drug reactions and interactionsScienceDirect ® is a registered trademark of Elsevier B.V. Comparison with other antiandrogens. Although only a handful of events occurred, the difference between the two arms was so dramatic that it was felt necessary to publish the results and, therefore, give collaborators a chance to offer patients therapy earlier than was initially planned.In the UK enzalutamide is licensed for the treatment of men with metastatic, castrate-resistant prostate cancer whose disease has progressed on or after docetaxel-based chemotherapy. The Journal of Clinical Endocrinology & Metabolism, 64(4), 763-770.De Voogt, H. J., Rao, B. R., Geldof, A. The maximal estradiol levels produced by bicalutamide approximate those of the low-normal female range. In further phase III studies, comparing Casodex 150 mg/day and castration, in patients with nonmetastatic disease (Further development of monotherapy with bicalutamide came from a large worldwide study with over 8000 patients that was completed in 2001, where patients following radical prostatectomy, definitive radiotherapy, or those being managed by a policy of surveillance, without evidence of disease progression were randomized to receive placebo or bicalutamide.